United Therapeutics Corporation $UTHR Shares Acquired by New England Research & Management Inc.

New England Research & Management Inc. increased its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 110.1% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,530 shares of the biotechnology company’s stock after purchasing an additional 1,850 shares during the quarter. New England Research & Management Inc.’s holdings in United Therapeutics were worth $1,913,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in UTHR. BlackRock Inc. acquired a new stake in shares of United Therapeutics in the second quarter valued at about $2,868,735,000. Jupiter Topco LLC acquired a new position in United Therapeutics during the second quarter valued at approximately $450,140,000. Bank of New York Mellon Corp acquired a new position in United Therapeutics during the second quarter valued at approximately $159,522,000. Caisse de depot et placement du Quebec bought a new position in United Therapeutics in the second quarter valued at approximately $154,304,000. Finally, Legal & General Group Plc bought a new position in United Therapeutics in the second quarter valued at approximately $112,209,000. Institutional investors own 94.08% of the company’s stock.

Analyst Upgrades and Downgrades

UTHR has been the topic of a number of analyst reports. The Goldman Sachs Group reiterated a “sell” rating and set a $368.00 price objective on shares of United Therapeutics in a research note on Thursday. Morgan Stanley increased their price objective on United Therapeutics from $515.00 to $566.00 and gave the company an “equal weight” rating in a report on Wednesday, October 7th. Royal Bank Of Canada raised their target price on shares of United Therapeutics from $677.00 to $708.00 and gave the company an “outperform” rating in a research note on Thursday, October 8th. Weiss Ratings downgraded shares of United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, August 27th. Finally, Bank of America dropped their price target on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research report on Friday, July 10th. Eleven equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $642.69.

United Therapeutics Stock Down 1.5%

Shares of UTHR stock traded down $8.39 during trading on Friday, reaching $533.12. 654,280 shares of the company’s stock were exchanged, compared to its average volume of 992,596. The stock has a market capitalization of $22.87 billion, a PE ratio of 19.07, a PEG ratio of 3.87 and a beta of 0.49. United Therapeutics Corporation has a twelve month low of $409.07 and a twelve month high of $609.35. The firm’s fifty day moving average price is $513.64 and its 200-day moving average price is $540.40.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, beating analysts’ consensus estimates of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%. The business had revenue of $783.30 million for the quarter, compared to analysts’ expectations of $804.65 million. During the same quarter in the prior year, the business earned $6.41 EPS. The firm’s revenue for the quarter was down 1.9% on a year-over-year basis. As a group, analysts anticipate that United Therapeutics Corporation will post 26.40 EPS for the current fiscal year.

Insider Buying and Selling at United Therapeutics

In other news, CEO Martine Rothblatt sold 9,500 shares of the firm’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $516.06, for a total transaction of $4,902,570.00. Following the completion of the sale, the chief executive officer owned 324,443 shares in the company, valued at approximately $167,432,054.58. This trade represents a 2.84% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders have sold 392,028 shares of company stock valued at $202,884,996 over the last 90 days. 8.60% of the stock is owned by corporate insiders.

Key Headlines Impacting United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: United Therapeutics settled six patent and antitrust disputes with Liquidia, reducing legal uncertainty around Liquidia’s YUTREPIA inhaled treprostinil treatment. The agreement limits YUTREPIA’s label, including excluding pulmonary hypertension associated with interstitial lung disease, which could help protect UTHR’s competitive position. United Therapeutics Settles Litigation And Resets Pulmonary Hypertension Competition
• Positive Sentiment: The settlement is expected to provide United Therapeutics with approximately $380.7 million in payments, while giving investors greater visibility into the competitive landscape for treprostinil therapies. United Therapeutics Stock May Be Undervalued Following the Litigation Settlement
• Positive Sentiment: Traders purchased 12,089 UTHR call options, roughly 220% above average daily volume. The activity signals increased bullish speculation, although options flow does not guarantee sustained buying in the shares.
• Positive Sentiment: Analyst sentiment remains generally favorable. Jefferies reaffirmed a Buy rating with a $728 target, and the broader analyst consensus remains “Moderate Buy,” with targets above recent trading levels.
• Neutral Sentiment: CEO Martine Rothblatt sold 9,500 shares for approximately $5.13 million, reducing her holdings by 2.84%. She still retains a substantial position, so the sale may reflect personal financial planning rather than a change in the company’s outlook. United Therapeutics CEO Stock Sale SEC Filing
• Negative Sentiment: EVP Paul Mahon sold 8,300 shares for approximately $4.52 million, cutting his direct stake by 15.52%. The second executive sale disclosed within two days may weigh on sentiment, even though insider transactions alone do not establish a deterioration in fundamentals. United Therapeutics EVP Stock Sale SEC Filing

United Therapeutics Company Profile

United Therapeutics Corporation is a biotechnology and pharmaceutical company focused on developing and commercializing therapies for pulmonary arterial hypertension (PAH) and other serious cardiopulmonary conditions. The company’s products include Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable form of treprostinil; Orenitram, an oral treprostinil product; and Adcirca, a tadalafil-based PAH treatment.

United Therapeutics markets its therapies primarily in the United States and internationally through commercial and regulatory activities in additional markets.